Dr.PulmRoch said:Read four things before the headline number.
This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.
From the other side of the consultation, briefly.
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.
A recent PSM study of 18,000 GLP-1 users vs matched controls showed reduced MI incidence (HR 0.78) over 4 years of follow-up[1].
These results complement the RCT data and suggest the benefits translate to real-world populations.
CarlaRPh_TPA said:The gap between trial results and real-world results is consistent and it is not fraud.
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:
The the trial evidence meta-analysis shows a pooled RR of 0.75 (95% CI 0.66-0.85), I²=33%. This is a robust and consistent effect.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAdmin said:WELCOME: Introduce yourself & read the community guidelines Welcome to Public Square.
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.
For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."
The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.
Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again.